Daken Medical Instruments’ consolidated results for the first quarter of fiscal year 2027 (ending March 2027) showed revenue of \u00a52,439 million (down 2.3% YoY), operating income of \u00a5214 million (down 23.9%), and net income of \u00a5167 million (down 22.3%). Despite increased costs impacting profits, steady sales were maintained.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"7775","jir_company_name":"Daken Medical Instruments Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-07-31","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/07\/7775-20260731-01.pdf","jir_short_summary":"Daken Medical Instruments' consolidated results for the first quarter of fiscal year 2027 (ending March 2027) showed revenue of \u00a52,439 million (down 2.3% YoY), operating income of \u00a5214 million (down 23.9%), and net income of \u00a5167 million (down 22.3%). Despite increased costs impacting profits, steady sales were maintained.","jir_summary":"### Financial Performance Overview\nDaken Medical Instruments' results for the first quarter of fiscal year 2027, ending March 2027, showed revenue of \u00a52,439 million (down 2.3% YoY), with increased costs leading to operating income of \u00a5214 million (down 23.9%) and net income of \u00a5167 million (down 22.3%). Revenue was supported by increased sales of injection-related products, though declines in suction device sales and rising material costs pressured profit margins. The company\u2019s financial position remains strong with total assets of \u00a511,076 million and an equity ratio of 68.6%. Going forward, the company plans to focus on cost management and supplying high-quality products to improve profitability.\n\n### Outlook and Impact on Shareholders\nThe current period\u2019s performance is generally in line with initial forecasts, with no revision necessary at this time. Continued efforts will be made to maintain stable sales and manage costs, supporting the supply of products that meet medical needs. The dividend forecast remains at \u00a520.00 per share, the same as for fiscal year ending March 2026, reflecting ongoing shareholder return policies. The company aims to enhance profitability and achieve steady business growth, providing an attractive investment proposition.","jir_financial_highlights":"Revenue: \u00a52,439 million (Compared to previous year -2.3%)\nOperating Income: \u00a5214 million (Compared to previous year -23.9%)\nNet Income for the Quarter: \u00a5167 million (Compared to previous year -22.3%)\nTotal Assets: \u00a511,076 million (Compared to previous year -\u00a5290 million)\nEquity Ratio: 68.6% (Compared to previous term +0.4 points)","jir_category":"","jir_hashtags":"#DakenMedicalInstruments, #FinancialResults, #JapaneseStocks","jir_key_figures":"Revenue: \u00a52,439 million (YoY -2.3%)\nNet Income: \u00a5167 million (YoY -22.3%)\nTotal Assets: \u00a511,076 million (Compared to previous term -\u00a5290 million)","jir_meta_title":"\u3010Daken Medical Instruments\u30112027 Q1 Financial Results | Revenue: \u00a52,439 million (YoY -2.3%)","jir_meta_description":"Summary of Daken Medical Instruments' financial results for the first quarter of fiscal year 2027. Revenue reached \u00a52,439 million, profits declined, but financial stability was maintained. Future outlook emphasized.","jir_og_title":"\u3010Daken Medical Instruments\u30112027 Q1 Financial Results | Revenue: \u00a52,439 million (YoY -2.3%)","jir_og_description":"Detailed overview of Daken Medical Instruments\u2019 Q1 FY2027 financial results. Explains revenue, profit trends, and future business prospects for investors.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":58413,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-92101","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n